SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
September
12, 2017
Commission
File Number 001-14978
SMITH & NEPHEW
plc
(Registrant's
name)
15 Adam
Street
London, England WC2N 6LA
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Appointment of Marc Owen as Non-Executive Director
12 September 2017
Smith & Nephew (LSE: SN, NYSE: SNN), the global medical
technology business, announces that Marc Owen is to join its Board
as Non-Executive Director on 1 October 2017. He will also
join the Audit Committee.
Marc Owen retired from Fortune 500 healthcare business McKesson
Corp in March 2017 where he had served on the Executive Committee
since 2001, holding a number of senior roles including Chairman of
the Management Board of integrated pharmaceuticals services
provider Celesio AG and President of the McKesson Speciality Health
business. Marc Owen also worked for McKinsey for 12 years,
specialising in healthcare and technology, and began his career as
a barrister in London.
Roberto Quarta, Chairman of Smith & Nephew,
commented:
"Marc Owen has proven himself as a leader with strategic vision who
has built significant international healthcare businesses.
Attracting such a strong candidate reflects well on the prospects
for Smith & Nephew and ensures the Board maintains our deep
commercial healthcare expertise when, as previously announced, Joe
Papa retires at the Annual General Meeting next year."
Marc Owen is a British citizen and is 57 years old.
No disclosure obligations arise under paragraphs (1) to (6) of LR
9.6.13 R of the UK Listing Authority's Listing Rules in respect of
this appointment. Marc Owen's fees will be $129,780 per annum of
which $9,780 will be paid in the form of Smith & Nephew shares
in-line with current Non-Executive Directors.
- ends
-
Enquiries
Investors
Ingeborg
Oie
Smith
& Nephew
|
+44 (0)
20 7401 7646
|
Media
Charles
Reynolds
Smith
& Nephew
|
+44 (0)
1923
477314
|
Ben
Atwell / Simon Conway
FTI
Strategic Consulting
|
+44 (0)
20 3727 1000
|
About Smith & Nephew
Smith
& Nephew is a global medical technology business dedicated to
helping healthcare professionals improve people's lives. With
leadership positions in Orthopaedic
Reconstruction, Advanced Wound
Management, Sports Medicine
and Trauma
& Extremities, Smith & Nephew has around 15,000
employees and a presence in more
than 100 countries. Annual sales in 2016 were almost $4.7
billion. Smith & Nephew is a member of the FTSE 100 (LSE:SN,
NYSE:SNN).
For
more information about Smith & Nephew, please visit our website
www.smith-nephew.com, follow @SmithNephewplc
on Twitter or
visit
SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
◊ Trademark of Smith & Nephew. Certain marks
registered US Patent and Trademark Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: September
12, 2017
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company Secretary